WO1998057636A1 - Treatment of diabetes with rosiglitazone and insulin - Google Patents

Treatment of diabetes with rosiglitazone and insulin Download PDF

Info

Publication number
WO1998057636A1
WO1998057636A1 PCT/EP1998/003692 EP9803692W WO9857636A1 WO 1998057636 A1 WO1998057636 A1 WO 1998057636A1 EP 9803692 W EP9803692 W EP 9803692W WO 9857636 A1 WO9857636 A1 WO 9857636A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
administration
insulin
pharmaceutically acceptable
diabetes
Prior art date
Application number
PCT/EP1998/003692
Other languages
French (fr)
Inventor
Stephen Alistair Smith
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HU0003260A priority Critical patent/HUP0003260A3/en
Priority to PL98343123A priority patent/PL343123A1/en
Priority to JP50375799A priority patent/JP2002504138A/en
Priority to BR9810444-6A priority patent/BR9810444A/en
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Priority to APAP/P/1999/001718A priority patent/AP1287A/en
Priority to UA99126881A priority patent/UA70299C2/en
Priority to EA200000042A priority patent/EA004800B1/en
Priority to SK1793-99A priority patent/SK179399A3/en
Priority to CA002294141A priority patent/CA2294141A1/en
Priority to EP98932169A priority patent/EP0999837A1/en
Priority to AU82163/98A priority patent/AU8216398A/en
Priority to IL13314398A priority patent/IL133143A0/en
Publication of WO1998057636A1 publication Critical patent/WO1998057636A1/en
Priority to NO996265A priority patent/NO996265D0/en
Priority to BG104059A priority patent/BG104059A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Definitions

  • This invention relates to a method of treatment, in particular to a method for the treatment of diabetes mellitus, especially non-insulin dependent diabetes (NIDDM) or Type II diabetes and conditions associated with diabetes mellitus.
  • NIDDM non-insulin dependent diabetes
  • Insulin is a front line treatment agent for Type I diabetes (or Insulin Dependent Diabetes). It is also used as an antihyperglycaemic agent in the treatment ofNIDDM.
  • European Patent Application, Publication Number 0,306,228 relates to certain thiazolidinedione derivatives disclosed as having antihyperglycaemic and hypolipidaemic activity.
  • One particular thiazolidinedione disclosed in EP 0306228 is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (hereinafter 'Compound (I)').
  • WO94/05659 discloses certain salts of Compound (I) including the maleate salt at example 1 thereof.
  • the invention provides a method for the treatment of diabetes mellitus, especially Type II diabetes and conditions associated with diabetes mellitus in a mammal such as a human, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of Compound (I) and insulin, to a mammal in need thereof.
  • the amount of Compound (I) administered is up to 12 mg, especially when administered per day.
  • the method comprises either co-administration of Compound (I) and insulin or the sequential administration thereof.
  • Co-administration includes administration of a formulation which includes both an insulin sensitiser, such as Compound (I), and insulin or, more suitably, the essentially simultaneous administration of separate formulations of each agent.
  • an insulin sensitiser such as Compound (I)
  • insulin or, more suitably, the essentially simultaneous administration of separate formulations of each agent.
  • the method comprises the administration of 2 to 12 mg of Compound (I), especially when admimstered per day.
  • the method comprises the administration of 2 to 4 , 4 to 8 or 8 to 12 mg of Compound (I) per day.
  • the method comprises the administration of 2 to 4mg of Compound (I), especially when administered per day.
  • the method comprises the administration of 4 to 8mg, such as greater than 4 for example 4.1, to 8 mg, of Compound (I), especially when administered per day.
  • the method comprises the administration of 8 to 12 mg of Compound (I), especially when administered per day.
  • the method comprises the administration of 2 mg of Compound
  • the method comprises the administration of 4 mg of Compound (I), especially when administered per day.
  • the method comprises the administration of 8 mg of Compound (I), especially when administered per day.
  • Compound (I) and the insulin are each administered in a pharmaceutically acceptable form, including for Compound (I), pharmaceutically acceptable derivatives such as pharmaceutically acceptable salts and solvates thereof.
  • Suitable pharmaceutically acceptable salted forms of Compound (I) include those described in EP 0306228 and WO94/05659.
  • a preferred pharmaceutically acceptable salt is a maleate.
  • Suitable pharmaceutically acceptable solvated forms of Compound (I) include those described in EP 0306228 and WO94/05659, in particular hydrates. Suitable pharmaceutically acceptable forms of insulin are referred to in standard reference texts such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.) and Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein).
  • Compound (I) or, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof may be prepared using known methods, for example those disclosed in EP 0306228 and WO94/05659. The disclosures of EP 0306228 and WO94/05659 are incorporated herein by reference.
  • Compound (I) may exist in one of several tautomeric forms, all of which are encompassed by the term Compound (I) as individual tautomeric forms or as mixtures thereof.
  • Compound (I) contains a chiral carbon atom, and hence can exist in one or more stereoisomeric forms, the term Compound (I) encompasses all of these isomeric forms whether as individual isomers or as mixtures of isomers, including racemates.
  • Insulin is prepared according to known methods, such methods are found or are referred to in standard reference texts, such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.) and Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein).
  • condition associated with diabetes includes conditions associated with diabetes mellitus itself and complications associated with diabetes mellitus.
  • 'Conditions associated with diabetes mellitus itself include hyperglycaemia, insulin resistance, including acquired insulin resistance and obesity. Further conditions associated with diabetes mellitus itself include hypertension and cardiovascular disease, especially atherosclerosis and conditions associated with insulin resistance. Conditions associated with insulin resistance include poly cystic ovarian syndrome and steroid induced insulin resistance and gestational diabetes. 'Complications associated with diabetes mellitus' includes renal disease, especially renal disease associated with Type II diabetes, neuropathy and retinopathy.
  • Renal diseases associated with Type II diabetes include nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis and end stage renal disease.
  • nephropathy glomerulonephritis
  • glomerular sclerosis glomerular sclerosis
  • nephrotic syndrome hypertensive nephrosclerosis
  • end stage renal disease end stage renal disease.
  • the term 'pharmaceutically acceptable' embraces both human and veterinary use: for example the term 'pharmaceutically acceptable' embraces a veterinarily acceptable compound.
  • scalar amounts including mg amounts, of Compound (I) in a pharmaceutically acceptable form
  • the scalar amount referred to is made in respect of Compound (I) per se:
  • 2 mg of Compound (I) in the form of the maleate salt is that amount of maleate salt which contains 2 mg of Compound (I).
  • Diabetes mellitus is preferably Type II diabetes.
  • the particularly beneficial effect on glycaemic control provided by the treatment of the invention is indicated to be a synergistic effect relative to the control expected for the sum of the effects of the individual active agents.
  • Glycaemic control may be characterised using conventional methods, for example by measurement of a typically used index of glycaemic control such as fasting plasma glucose or glycosylated haemoglobin (Hb Ale). Such indices are determined using standard methodology, for example those described in: Tuescher A, Richterich, P., Sau. med. Wschr. 101 (1971), 345 and 390 and Frank P., 'Monitoring the Diabetic Patent with Glycosolated Hemoglobin Measurements', Clinical Products 1988
  • the dosage level of each of the active agents when used in accordance with the treatment of the invention will be less than would have been required from a purely additive effect upon glycaemic control.
  • the active medicaments are preferably administered in pharmaceutical composition form.
  • such compositions can include both medicaments or one only of the medicaments.
  • compositions, formulations and methods of administration suitably refer to the compositions, formulations and administration of Compound (I).
  • compositions are adapted for oral administration. However, they may be adapted for other modes of administration, for example parenteral administration, sublingual or transdermal administration.
  • the compositions may be in the form of tablets, capsules, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations, such as oral or sterile parenteral solutions or suspensions.
  • Unit dose presentation forms for oral administration may be tablets and capsules and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycoUate or microcrystalline cellulose; or pharmaceutically acceptable wetting agents such as sodium lauryl sulphate.
  • binding agents for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone
  • fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine
  • tabletting lubricants for example magnesium stearate
  • disintegrants for example star
  • the solid oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are of course conventional in the art.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.
  • Oral liquid preparations may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.
  • suspending agents for example sorbitol, syrup, methyl cellulose,
  • fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, and, depending on the concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, a preservative and buffering agents can be dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner, except that the Compound (I)s suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration.
  • the compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • Compositions may contain from 0.1% to 99% by weight, preferably from 10-60% by weight, of the active material, depending upon the method of administration.
  • compositions may, if desired, be in the form of a pack accompanied by written or printed instructions for use.
  • compositions are formulated according to conventional methods, such as those disclosed herein and in standard reference texts, for example the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.) and Martindale The Extra Pharmacopoeia (London The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein) and Harry's Cosmeticology (Leonard Hill Books).
  • the compositions are preferably in a unit dosage form in an amount appropriate for the relevant daily dosage.
  • Suitable dosages including unit dosages of the Compound of formula (I) comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 mg of Compound (I).
  • the two medicaments may be administered from 1 to 6 times a day, but most preferably 1 or 2 times per day.
  • Suitable dosages of insulin include those described or referred to in reference texts such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.) and Martindale The * Extra Pharmacopoeia (London, The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein).
  • a range of 2 to 4mg includes a range of 2.1 to 4, 2.2 to 4, 2.3 to 4, 2.4 to 4, 2.5 to 4, 2.6 to 4, 2.7 to 4, 2.8 to 4, 2.9 to 4 or 3 to 4mg.
  • a range of 4 to 8mg includes a range of 4.1 to 8, 4.2 to 8, 4.3 to 8, 4.4 to 8,
  • a range of 8 to 12 mg includes a range of 8.1 to 12, 8.2 to 12, 8.3 to 12, 8.4 to 12, 8.5 to 12, 8.6 to 12, 8.7 to 12, 8.8 to 12, 8.9 to 12, 9 to 12, 10 to 12 or 11 to 12mg. No adverse toxicological effects have been established for the compositions or methods of the invention in the abovementioned dosage ranges.
  • lactose monohydrate is passed through a suitable screen and blended with the milled maleate salt of Compound (I).
  • Sodium starch glycoUate, hydoxypropyl methylcellulose, microcrystalline cellulose and the remaining lactose are passed through a suitable screen and added to the mixture. Blending is then continued.
  • the resulting mixture is then wet granulated with purified water.
  • the wet granules are then screened, dried on a fluid bed drier and the dried granules are passed through a further screen and finally homogenised.
  • the granules from above are placed into a tumble blender. Approximately two thirds of the lactose is screened and added to the blender. The microcrystalline cellulose, sodium starch glycoUate, magnesium stearate and remaining lactose are screened and added to the blender and the mixture blended together. The resulting mix is then compressed on a rotary tablet press to a target weight of 150mg for the 1, 2 and 4mg tablets and to a target weight of 300mg for the 8mg tablets. The tablet cores are then transferred to a tablet coating machine, pre-warmed with warm air (approximately 65°C) and film coated until the tablet weight has increased by 2.0% to 3.5%.
  • Aqueous film coating material 4.5 4.5 4.5 9.0

Abstract

A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of Compound (I) and insulin to a mammal in need thereof.

Description

TREATMENT OF DIABETES WITH ROSIGLITAZONE AND INSULIN
This invention relates to a method of treatment, in particular to a method for the treatment of diabetes mellitus, especially non-insulin dependent diabetes (NIDDM) or Type II diabetes and conditions associated with diabetes mellitus.
Insulin is a front line treatment agent for Type I diabetes (or Insulin Dependent Diabetes). It is also used as an antihyperglycaemic agent in the treatment ofNIDDM.
European Patent Application, Publication Number 0,306,228 relates to certain thiazolidinedione derivatives disclosed as having antihyperglycaemic and hypolipidaemic activity. One particular thiazolidinedione disclosed in EP 0306228 is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (hereinafter 'Compound (I)'). WO94/05659 discloses certain salts of Compound (I) including the maleate salt at example 1 thereof. International Patent Application, publication number WO97/05875 discloses a method for reducing the amount of exogenous insulin admimstered to a patient having NIDDM by administering a therapeutically effective amount of a thiazolidinedione derivative and or a related compound.
It is now surprisingly indicated that a specific amount of Compound (I) in combination with insulin provides a particularly beneficial effect on glycaemic control, such combination is therefore particularly useful for the treatment of diabetes mellitus, especially Type II diabetes and conditions associated with diabetes mellitus.
Accordingly, the invention provides a method for the treatment of diabetes mellitus, especially Type II diabetes and conditions associated with diabetes mellitus in a mammal such as a human, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of Compound (I) and insulin, to a mammal in need thereof.
Preferably, the amount of Compound (I) administered is up to 12 mg, especially when administered per day. The method comprises either co-administration of Compound (I) and insulin or the sequential administration thereof.
Co-administration includes administration of a formulation which includes both an insulin sensitiser, such as Compound (I), and insulin or, more suitably, the essentially simultaneous administration of separate formulations of each agent.
In one particular aspect, the method comprises the administration of 2 to 12 mg of Compound (I), especially when admimstered per day. Particularly, the method comprises the administration of 2 to 4 , 4 to 8 or 8 to 12 mg of Compound (I) per day.
Particularly, the method comprises the administration of 2 to 4mg of Compound (I), especially when administered per day. Particularly, the method comprises the administration of 4 to 8mg, such as greater than 4 for example 4.1, to 8 mg, of Compound (I), especially when administered per day.
Particularly, the method comprises the administration of 8 to 12 mg of Compound (I), especially when administered per day. Preferably, the method comprises the administration of 2 mg of Compound
(I), especially when administered per day.
Preferably, the method comprises the administration of 4 mg of Compound (I), especially when administered per day.
Preferably, the method comprises the administration of 8 mg of Compound (I), especially when administered per day.
It will be understood that Compound (I) and the insulin are each administered in a pharmaceutically acceptable form, including for Compound (I), pharmaceutically acceptable derivatives such as pharmaceutically acceptable salts and solvates thereof. Suitable pharmaceutically acceptable salted forms of Compound (I) include those described in EP 0306228 and WO94/05659. A preferred pharmaceutically acceptable salt is a maleate.
Suitable pharmaceutically acceptable solvated forms of Compound (I) include those described in EP 0306228 and WO94/05659, in particular hydrates. Suitable pharmaceutically acceptable forms of insulin are referred to in standard reference texts such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.) and Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein).
Compound (I) or, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, may be prepared using known methods, for example those disclosed in EP 0306228 and WO94/05659. The disclosures of EP 0306228 and WO94/05659 are incorporated herein by reference.
Compound (I) may exist in one of several tautomeric forms, all of which are encompassed by the term Compound (I) as individual tautomeric forms or as mixtures thereof. Compound (I) contains a chiral carbon atom, and hence can exist in one or more stereoisomeric forms, the term Compound (I) encompasses all of these isomeric forms whether as individual isomers or as mixtures of isomers, including racemates. Insulin is prepared according to known methods, such methods are found or are referred to in standard reference texts, such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.) and Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein).
When used herein the term 'conditions associated with diabetes' includes conditions associated with diabetes mellitus itself and complications associated with diabetes mellitus.
'Conditions associated with diabetes mellitus itself include hyperglycaemia, insulin resistance, including acquired insulin resistance and obesity. Further conditions associated with diabetes mellitus itself include hypertension and cardiovascular disease, especially atherosclerosis and conditions associated with insulin resistance. Conditions associated with insulin resistance include poly cystic ovarian syndrome and steroid induced insulin resistance and gestational diabetes. 'Complications associated with diabetes mellitus' includes renal disease, especially renal disease associated with Type II diabetes, neuropathy and retinopathy.
Renal diseases associated with Type II diabetes include nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis and end stage renal disease. As used herein the term 'pharmaceutically acceptable' embraces both human and veterinary use: for example the term 'pharmaceutically acceptable' embraces a veterinarily acceptable compound.
For the avoidance of doubt, when reference is made herein to scalar amounts, including mg amounts, of Compound (I) in a pharmaceutically acceptable form, the scalar amount referred to is made in respect of Compound (I) per se: For example 2 mg of Compound (I) in the form of the maleate salt is that amount of maleate salt which contains 2 mg of Compound (I).
Diabetes mellitus is preferably Type II diabetes. The particularly beneficial effect on glycaemic control provided by the treatment of the invention is indicated to be a synergistic effect relative to the control expected for the sum of the effects of the individual active agents.
Glycaemic control may be characterised using conventional methods, for example by measurement of a typically used index of glycaemic control such as fasting plasma glucose or glycosylated haemoglobin (Hb Ale). Such indices are determined using standard methodology, for example those described in: Tuescher A, Richterich, P., Schweiz. med. Wschr. 101 (1971), 345 and 390 and Frank P., 'Monitoring the Diabetic Patent with Glycosolated Hemoglobin Measurements', Clinical Products 1988 In a preferred aspect, the dosage level of each of the active agents when used in accordance with the treatment of the invention will be less than would have been required from a purely additive effect upon glycaemic control.
In the method of the invention, the active medicaments are preferably administered in pharmaceutical composition form. As indicated above, such compositions can include both medicaments or one only of the medicaments.
In the treatment of the invention, insulin is usually administered by injection or by other known methods, for example those described in the reference texts mentioned herein. Thus the following comments relating to compositions, formulations and methods of administration suitably refer to the compositions, formulations and administration of Compound (I).
Usually the compositions are adapted for oral administration. However, they may be adapted for other modes of administration, for example parenteral administration, sublingual or transdermal administration. The compositions may be in the form of tablets, capsules, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations, such as oral or sterile parenteral solutions or suspensions.
In order to obtain consistency of administration it is preferred that a composition of the invention is in the form of a unit dose. Unit dose presentation forms for oral administration may be tablets and capsules and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycoUate or microcrystalline cellulose; or pharmaceutically acceptable wetting agents such as sodium lauryl sulphate.
The solid oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are of course conventional in the art. The tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.
Oral liquid preparations may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.
For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, and, depending on the concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, a preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the Compound (I)s suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration. The compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
Compositions may contain from 0.1% to 99% by weight, preferably from 10-60% by weight, of the active material, depending upon the method of administration.
Compositions may, if desired, be in the form of a pack accompanied by written or printed instructions for use.
The compositions are formulated according to conventional methods, such as those disclosed herein and in standard reference texts, for example the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.) and Martindale The Extra Pharmacopoeia (London The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein) and Harry's Cosmeticology (Leonard Hill Books). The compositions are preferably in a unit dosage form in an amount appropriate for the relevant daily dosage.
Suitable dosages including unit dosages of the Compound of formula (I) comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 mg of Compound (I).
In the treatments the two medicaments may be administered from 1 to 6 times a day, but most preferably 1 or 2 times per day.
Suitable dosages of insulin, including unit dosages, include those described or referred to in reference texts such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.) and Martindale The* Extra Pharmacopoeia (London, The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein).
A range of 2 to 4mg includes a range of 2.1 to 4, 2.2 to 4, 2.3 to 4, 2.4 to 4, 2.5 to 4, 2.6 to 4, 2.7 to 4, 2.8 to 4, 2.9 to 4 or 3 to 4mg. A range of 4 to 8mg includes a range of 4.1 to 8, 4.2 to 8, 4.3 to 8, 4.4 to 8,
4.5 to 8, 4.6 to 8, 4.7 to 8, 4.8 to 8, 4.9 to 8, 5 to 8, 6 to 8 or 7 to 8mg.
A range of 8 to 12 mg includes a range of 8.1 to 12, 8.2 to 12, 8.3 to 12, 8.4 to 12, 8.5 to 12, 8.6 to 12, 8.7 to 12, 8.8 to 12, 8.9 to 12, 9 to 12, 10 to 12 or 11 to 12mg. No adverse toxicological effects have been established for the compositions or methods of the invention in the abovementioned dosage ranges.
The following example illustrates the invention but does not limit it in any way.
COMPOUND (I) COMPOSITIONS
A Concentrate Preparation
Approximately two thirds of the lactose monohydrate is passed through a suitable screen and blended with the milled maleate salt of Compound (I). Sodium starch glycoUate, hydoxypropyl methylcellulose, microcrystalline cellulose and the remaining lactose are passed through a suitable screen and added to the mixture. Blending is then continued. The resulting mixture is then wet granulated with purified water. The wet granules are then screened, dried on a fluid bed drier and the dried granules are passed through a further screen and finally homogenised.
% COMPOSITION OF GRANULAR CONCENTRATE
Ingredient Quantity (%)
Milled Compound (I) as maleate 13.25 (pure salt maleate salt)
Sodium Starch GlycoUate 5.00
Hydoxypropyl Methylcellulose 5.00 2910
Microcrystalline Cellulose 20.0
Lactose Monohydrate, regular to 100 grade
Purified water *
* Removed during processing.
B Formulation of the concentrate into tablets.
The granules from above are placed into a tumble blender. Approximately two thirds of the lactose is screened and added to the blender. The microcrystalline cellulose, sodium starch glycoUate, magnesium stearate and remaining lactose are screened and added to the blender and the mixture blended together. The resulting mix is then compressed on a rotary tablet press to a target weight of 150mg for the 1, 2 and 4mg tablets and to a target weight of 300mg for the 8mg tablets. The tablet cores are then transferred to a tablet coating machine, pre-warmed with warm air (approximately 65°C) and film coated until the tablet weight has increased by 2.0% to 3.5%.
Quantity (mg per Tablet)
Tablet Strength l.Omg 2.0mg 4.0mg 8.0mg
Active Ingredient:
Compound (I) maleate Concentrate granules 10.00 20.00 40.00 80.00
Other Ingredients:
Sodium Starch GlycoUate 6.96 6.46 5.46 10.92
Microcrystalline Cellulose 27.85 25.85 21.85 43.70
Lactose monohydrate 104.44 96.94 81.94 163.88
Magnesium Stearate 0.75 0.75 0.75 1.50
Total Weight of Tablet Core 150.0 150.0 150.0 300.0
Aqueous film coating material 4.5 4.5 4.5 9.0
Total Weight of Film Coated Tablet 154.5 154.5 154.5 309.0

Claims

Claims
1. A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of Compound (I) and insulin, to a mammal in need thereof.
2. A method according to claim 1 , which comprises the administration of up to 12 mg of Compound (I).
3. A method according to claim 1 or claim 2, which comprises the administration of 2 to 12 mg of Compound (I).
4. A method according to any one of claims 1 to 3, which comprises the administration of 2 to 4, 4 to 8 or 8 to 12 mg of Compound (I).
5. A method according to any one of claims 1 to 3, which comprises the administration of 2 to 4mg of Compound (I).
6. A method according to any one of claims 1 to 3, which comprises the administration of 4 to 8mg of Compound (I).
7. A method according to any one of claims 1 to 3, which comprises the administration of 8 to 12 mg of Compound (I).
8. A method according to any one of claims 1 to 3, which comprises the administration of 2 mg of Compound (I).
9. A method according to any one of claims 1 to 3, which comprises the administration of 4 mg of Compound (I).
10. A method according to any one of claims 1 to 3, which comprises the administration of 8 mg of Compound (I).
11. A pharmaceutical composition comprising Compound (I), insulin and a pharmaceutically acceptable carrier therefor.
12. A composition according to claim 11 , wherein the insulin sensitiser is Compound (I)
13. A composition according to claim 1 1 or claim 12, which comprises up to 12 mg or 2 to 12 mg of Compound (I).
14. A pharmaceutical composition comprising Compound (I), insulin and a pharmaceutically acceptable carrier therefor, for use as an active therapeutic substance.
15. A pharmaceutical composition comprising Compound (I), insulin and a pharmaceutically acceptable carrier therefor, for use in the treatment of diabetes mellitus and conditions associated with diabetes mellitus.
PCT/EP1998/003692 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin WO1998057636A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
UA99126881A UA70299C2 (en) 1997-06-18 1998-06-15 Method for treatment of diabetes mellitus with rosmethod for treatment of diabetes mellitus with rosiglitazon and insulin iglitazon and insulin
JP50375799A JP2002504138A (en) 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin
BR9810444-6A BR9810444A (en) 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin
SK1793-99A SK179399A3 (en) 1997-06-18 1998-06-15 Use of insulin sensitiser and an insulin
APAP/P/1999/001718A AP1287A (en) 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin.
PL98343123A PL343123A1 (en) 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin
EA200000042A EA004800B1 (en) 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin
HU0003260A HUP0003260A3 (en) 1997-06-18 1998-06-15 Pharmaceutical composition for treatment of diabetes with rosiglitazone and insulin
CA002294141A CA2294141A1 (en) 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin
EP98932169A EP0999837A1 (en) 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin
AU82163/98A AU8216398A (en) 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin
IL13314398A IL133143A0 (en) 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin
NO996265A NO996265D0 (en) 1997-06-18 1999-12-17 Treatment of diabetes with rosiglitazone and insulin
BG104059A BG104059A (en) 1997-06-18 2000-01-06 Diabetes treatment with rosiglytazone and insulin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712866.4A GB9712866D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GB9712866.4 1997-06-18

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09445858 A-371-Of-International 1999-12-15
US09/928,326 Continuation US20020028768A1 (en) 1997-06-18 2001-08-13 Treatment of diabetes with rosiglitazone and insulin

Publications (1)

Publication Number Publication Date
WO1998057636A1 true WO1998057636A1 (en) 1998-12-23

Family

ID=10814527

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/003692 WO1998057636A1 (en) 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin

Country Status (30)

Country Link
EP (1) EP0999837A1 (en)
JP (1) JP2002504138A (en)
KR (1) KR20010013843A (en)
CN (1) CN1133431C (en)
AP (1) AP1287A (en)
AR (2) AR012997A1 (en)
AU (1) AU8216398A (en)
BG (1) BG104059A (en)
BR (1) BR9810444A (en)
CA (1) CA2294141A1 (en)
CO (1) CO4940454A1 (en)
DZ (1) DZ2521A1 (en)
EA (1) EA004800B1 (en)
GB (1) GB9712866D0 (en)
HU (1) HUP0003260A3 (en)
ID (1) ID23951A (en)
IL (1) IL133143A0 (en)
IN (1) IN189723B (en)
MA (1) MA26511A1 (en)
NO (1) NO996265D0 (en)
OA (1) OA11517A (en)
PE (1) PE104499A1 (en)
PL (1) PL343123A1 (en)
SK (1) SK179399A3 (en)
TR (1) TR199903095T2 (en)
TW (1) TW587937B (en)
UA (1) UA70299C2 (en)
UY (1) UY25050A1 (en)
WO (1) WO1998057636A1 (en)
ZA (1) ZA985237B (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078333A2 (en) * 1999-06-21 2000-12-28 Eli Lilly And Company Synergetic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependant diabetes
WO2001000223A2 (en) * 1999-06-25 2001-01-04 Minimed Inc. Multiple agent diabetes therapy
WO2002004024A1 (en) * 2000-06-30 2002-01-17 Rieveley Robert B Composition for the treatment of diabetes
US6468507B1 (en) * 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
WO2002100396A1 (en) * 2001-06-07 2002-12-19 Wyeth COMBINATION OF A PTPase INHIBITOR AND A THIAZOLIDINEDIONE AGENT
US6531461B1 (en) 2001-06-04 2003-03-11 Louis Obyo Obyo Nelson Medicament for the treatment of diabetes
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
WO2004041275A1 (en) * 2002-11-08 2004-05-21 F. Hoffmann-La Roche Ag Substituted 4-alkoxyoxazol derivatives as ppar agonists
US6852694B2 (en) 2001-02-21 2005-02-08 Medtronic Minimed, Inc. Stabilized insulin formulations
EP1795531A1 (en) * 2000-09-29 2007-06-13 Smithkline Beecham Plc A thiazolidinedione derivative and its use as antidiabetic
US7264813B2 (en) * 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
EP1903043A1 (en) 1999-04-23 2008-03-26 SmithKline Beecham P.L.C. Novel pharmaceutical
US7595333B2 (en) 1999-04-14 2009-09-29 Takeda Pharmaceutical Company Limited Agent for improving acidosis

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102389427A (en) * 2011-10-10 2012-03-28 成都恒瑞制药有限公司 Solid oral preparation containing rosiglitazone and cetirizine hydrochloride

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007694A1 (en) * 1993-09-15 1995-03-23 Sankyo Company, Limited Use of thiazolidinediones to prevent or delay onset of niddm
WO1997005875A2 (en) * 1995-08-10 1997-02-20 Warner-Lambert Company A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
WO1997010819A1 (en) * 1995-09-18 1997-03-27 Ligand Pharmaceuticals Incorporated Treating niddm with rxr agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007694A1 (en) * 1993-09-15 1995-03-23 Sankyo Company, Limited Use of thiazolidinediones to prevent or delay onset of niddm
WO1997005875A2 (en) * 1995-08-10 1997-02-20 Warner-Lambert Company A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
WO1997010819A1 (en) * 1995-09-18 1997-03-27 Ligand Pharmaceuticals Incorporated Treating niddm with rxr agonists

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CONNOR SC ET AL: "Antidiabetic efficacy of BRL 49653, a potent orally active insulin sensitizing agent, assessed in the C57BL/KsJ db/db diabetic mouse by non-invasive 1H NMR studies of urine.", J PHARM PHARMACOL, MAR 1997, 49 (3) P336-44, ENGLAND, XP002080751 *
LEFEBVRE PJ ET AL: "Improving the action of insulin.", CLIN INVEST MED, AUG 1995, 18 (4) P340-7, CANADA, XP002080750 *
NEYROLLES N. ET AL: "New therapeutic agents of non insulindependent diabetes", ANNALES D'ENDOCRINOLOGIE, 1998, 59/2 (67-77), France, XP002080748 *
SKYLER J.S.: "Insulin therapy in type II diabetes: Who needs it, how much of it, and for how long?", POSTGRADUATE MEDICINE, 1997, 101/2 (85-90+92-94+96), USA, XP002080749 *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595333B2 (en) 1999-04-14 2009-09-29 Takeda Pharmaceutical Company Limited Agent for improving acidosis
EP1903043A1 (en) 1999-04-23 2008-03-26 SmithKline Beecham P.L.C. Novel pharmaceutical
WO2000078333A3 (en) * 1999-06-21 2001-07-12 Lilly Co Eli Synergetic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependant diabetes
US7223728B2 (en) 1999-06-21 2007-05-29 Eli Lilly And Company Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat metabolic instability associated with non-insulin dependent diabetes
USRE40876E1 (en) 1999-06-21 2009-08-18 Eli Lilly And Company Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagonlike peptide-1 and agonists thereof
EP1849475A1 (en) * 1999-06-21 2007-10-31 Eli Lilly & Company Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependent diabetes
US6660716B1 (en) 1999-06-21 2003-12-09 Eli Lilly And Company Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagon-like peptide-1 and agonists thereof
WO2000078333A2 (en) * 1999-06-21 2000-12-28 Eli Lilly And Company Synergetic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependant diabetes
WO2001000223A2 (en) * 1999-06-25 2001-01-04 Minimed Inc. Multiple agent diabetes therapy
WO2001000223A3 (en) * 1999-06-25 2001-05-25 Minimed Inc Multiple agent diabetes therapy
US7323543B2 (en) 1999-06-25 2008-01-29 Minimed, Inc. Multiple agent diabetes therapy
EP1305053A1 (en) * 2000-05-01 2003-05-02 Aeropharm Technology Incorporated A medicinal aerosol formulation
EP1305053A4 (en) * 2000-05-01 2009-04-29 Aeropharm Technology Inc A medicinal aerosol formulation
US6468507B1 (en) * 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
WO2002004024A1 (en) * 2000-06-30 2002-01-17 Rieveley Robert B Composition for the treatment of diabetes
EP1795531A1 (en) * 2000-09-29 2007-06-13 Smithkline Beecham Plc A thiazolidinedione derivative and its use as antidiabetic
EP1325000B1 (en) * 2000-09-29 2007-07-25 Smithkline Beecham Plc A thiazolidinedione derivative and its use as antidiabetic
US6852694B2 (en) 2001-02-21 2005-02-08 Medtronic Minimed, Inc. Stabilized insulin formulations
US6531461B1 (en) 2001-06-04 2003-03-11 Louis Obyo Obyo Nelson Medicament for the treatment of diabetes
WO2002100396A1 (en) * 2001-06-07 2002-12-19 Wyeth COMBINATION OF A PTPase INHIBITOR AND A THIAZOLIDINEDIONE AGENT
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
US7109225B2 (en) 2002-11-08 2006-09-19 Hofmann-La Roche Inc. Substituted oxazole derivatives
WO2004041275A1 (en) * 2002-11-08 2004-05-21 F. Hoffmann-La Roche Ag Substituted 4-alkoxyoxazol derivatives as ppar agonists
US7264813B2 (en) * 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
US7763255B2 (en) 2003-09-24 2010-07-27 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
US8343549B2 (en) 2003-09-24 2013-01-01 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder

Also Published As

Publication number Publication date
OA11517A (en) 2004-02-04
TW587937B (en) 2004-05-21
CA2294141A1 (en) 1998-12-23
BR9810444A (en) 2000-09-05
AR015894A1 (en) 2001-05-30
UA70299C2 (en) 2004-10-15
AP1287A (en) 2004-06-26
ID23951A (en) 2000-06-08
NO996265L (en) 1999-12-17
JP2002504138A (en) 2002-02-05
AP9901718A0 (en) 1999-12-31
SK179399A3 (en) 2000-11-07
ZA985237B (en) 2000-02-17
GB9712866D0 (en) 1997-08-20
AR012997A1 (en) 2000-11-22
BG104059A (en) 2000-10-31
HUP0003260A3 (en) 2001-12-28
KR20010013843A (en) 2001-02-26
MA26511A1 (en) 2004-12-20
EA200000042A1 (en) 2000-08-28
EP0999837A1 (en) 2000-05-17
EA004800B1 (en) 2004-08-26
UY25050A1 (en) 2000-09-29
TR199903095T2 (en) 2000-08-21
PL343123A1 (en) 2001-07-30
IL133143A0 (en) 2001-03-19
CO4940454A1 (en) 2000-07-24
DZ2521A1 (en) 2003-02-08
HUP0003260A2 (en) 2001-05-28
CN1260715A (en) 2000-07-19
AU8216398A (en) 1999-01-04
CN1133431C (en) 2004-01-07
IN189723B (en) 2003-04-19
NO996265D0 (en) 1999-12-17
PE104499A1 (en) 2000-01-13

Similar Documents

Publication Publication Date Title
EP0996444B1 (en) Treatment of diabetes with thiazolidinedione and metformin
US20050059706A1 (en) Treatment of diabetes with thiazolidinedione and metformin
US20080058388A1 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
AP1287A (en) Treatment of diabetes with rosiglitazone and insulin.
EP0999845B1 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
US20040106543A1 (en) Treatment of diabetes with rosiglitazone and insulin
NZ501345A (en) Treatment of diabetes mellitus with 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (2-12 mg) and an alpha-glucosidase inhibitor antihyperglycemic agent
EP0998291A1 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
AU783539B2 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
NZ518076A (en) 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (BRL49653) for treating non-insulin dependent diabetes (NIDDM)
AU778947B2 (en) Treatment of diabetes with thiazolidinedione and metformin
AU1552102A (en) Treatment of diabetes with rosiglitazone and insulin
US20020123514A1 (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
MXPA99012065A (en) Treatment of diabetes with rosiglitazone and insulin
NZ520542A (en) Treatment of diabetes with thiazolidinedione and metformin

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 133143

Country of ref document: IL

Ref document number: 98806223.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1998932169

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 501259

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 82163/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999/03095

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: PV1999-4579

Country of ref document: CZ

Ref document number: 09445858

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2294141

Country of ref document: CA

Ref document number: 2294141

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 179399

Country of ref document: SK

Ref document number: 1019997011864

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/012065

Country of ref document: MX

Ref document number: 1199901081

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 200000042

Country of ref document: EA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998932169

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019997011864

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV1999-4579

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: PV1999-4579

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1998932169

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1019997011864

Country of ref document: KR